Structure Therapeutics Valuation
| GPCR Stock | 19.94 0.40 1.97% |
At this time, the company appears to be undervalued. Structure Therapeutics has a current Real Value of USD35.87 per share. The regular price of the company is USD19.94. Our model measures the value of Structure Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 57.34 M, return on equity of -0.19, and Price To Book of 1.33 X as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Structure Therapeutics' valuation include:
Undervalued
Today
Please note that Structure Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Structure Therapeutics is based on 3 months time horizon. Increasing Structure Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Structure stock is determined by what a typical buyer is willing to pay for full or partial control of Structure Therapeutics American. Since Structure Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Structure Stock. However, Structure Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.94 | Real 35.87 | Target 83.0 | Hype 19.55 | Naive 18.02 |
The intrinsic value of Structure Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Structure Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Structure Therapeutics American helps investors to forecast how Structure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Structure Therapeutics more accurately as focusing exclusively on Structure Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Structure Therapeutics' intrinsic value based on its ongoing forecasts of Structure Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Structure Therapeutics' closest peers.
Structure Therapeutics Cash |
|
Structure Valuation Trend
Structure Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Structure Therapeutics' financial worth over time. Using both Structure Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Structure Therapeutics Total Value Analysis
Structure Therapeutics American is currently forecasted to have valuation of 267.2 M with market capitalization of 1.17 B, debt of 3.86 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Structure Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
267.2 M | 1.17 B | 3.86 M |
Structure Therapeutics Asset Utilization
One of the ways to look at asset utilization of Structure is to check how much profit was generated for every dollar of assets it reports. Structure Therapeutics has a negative utilization of assets of -0.14 %, losing USD0.001428 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Structure Therapeutics American shows how discouraging it operates for each dollar spent on its assets.Structure Therapeutics Ownership Allocation
The majority of Structure Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Structure Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Structure Therapeutics. Please pay attention to any change in the institutional holdings of Structure Therapeutics American as this could imply that something significant has changed or is about to change at the company. On November 1, 2023, Senator Thomas R Carper of US Senate acquired under $15k worth of Structure Therapeutics's common stock.Structure Therapeutics Profitability Analysis
Net Loss for the year was (122.53 M) with profit before overhead, payroll, taxes, and interest of 0.About Structure Therapeutics Valuation
The stock valuation mechanism determines Structure Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Structure Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Structure Therapeutics. We calculate exposure to Structure Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Structure Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -854.3 K | -811.5 K |
Structure Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Structure Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 582.9 M |
Structure Therapeutics Current Valuation Indicators
Structure Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Structure Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Structure Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Structure Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Structure Therapeutics' worth.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.